<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451046</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00839-40</org_study_id>
    <nct_id>NCT02451046</nct_id>
  </id_info>
  <brief_title>Usefulness of Alpha-GST in Liver Transplantation</brief_title>
  <acronym>GST-LT</acronym>
  <official_title>Predictive Ability of Alpha-GST to Detect Graft Primary Dysfunction After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaujon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beaujon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the ability of plasma alpha-GST
      measurements in liver donor (at the time of organ removal) to predict primary dysfunction in
      liver recipient. The secondary objective was to study the relationship between alpha-GST
      levels in the plasma of the liver transplant recipient and early graft function recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft primary dysfunction (PDF) after liver transplantation is enhanced by the increasing use
      of extended-criteria allografts. This complication is burdened with high mortality and
      morbidity rates among liver transplant recipients. Alpha-GST is a short-life hepatocyte
      enzyme that may be an interesting biomarker for liver injury. A recently developped ELISA
      technique may allow fast and easy measurement of alpha-GST plasma concentration (Fastpack IP
      α-GST Immunoassay, Qualigen Inc., Carlsbad, CA). This study aims to evaluate the ability of
      plasma alpha-GST measurements in liver donor to predict PDF in liver recipient. Methods:
      Observational study conducted in one center (Beaujon hospital, APHP, Clichy, France).
      Measurements of plasma levels of alpha-GST using Fastpack IP α-GST Immunoassay (Qualigen
      Inc., Carlsbad, CA) at the time of organ removal in liver donor and daily from day 0 to day 7
      after liver transplantation in recipients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Primary dysfunction (PDF) of liver graft</measure>
    <time_frame>First week</time_frame>
    <description>To evaluate the ability of plasma alpha-GST measurements in liver donor (at the time of organ removal) to PDF in liver recipient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early graft function recovery.</measure>
    <time_frame>First week</time_frame>
    <description>To study the relationship between alpha-GST levels in the plasma of the liver transplant recipient and early graft function recovery.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France )

        Exclusion Criteria:

          -  age &gt;70 years and &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Paugam-Burtz, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Paugam-Burtz, MD-PhD</last_name>
    <phone>140875610</phone>
    <phone_ext>+33</phone_ext>
    <email>catherine.paugam@bjn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel Weiss, MD</last_name>
    <phone>603004193</phone>
    <phone_ext>+33</phone_ext>
    <email>manuweiss@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Réanimation hépato-digestive</name>
      <address>
        <city>Clichy</city>
        <zip>F-92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Paugam-Burtz, MD-PhD</last_name>
      <phone>140875610</phone>
      <phone_ext>+33</phone_ext>
      <email>catherine.paugam@bjn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Weiss, MD</last_name>
      <phone>603004193</phone>
      <phone_ext>+33</phone_ext>
      <email>manuweiss@yahoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beaujon Hospital</investigator_affiliation>
    <investigator_full_name>Paugam-Burtz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Primary dysfunction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

